Company news

Capricor Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - CAPR

August 28, 2025

September 15, 2025 Deadline Approaching: Join Class Action Against Capricor Therapeutics, Inc. (CAPR) - Contact Levi & Korsinsky

August 26, 2025

Contact The Gross Law Firm by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)

August 25, 2025

Shareholders of Capricor Therapeutics, Inc. (CAPR): Protect Your Rights Before September 15, 2025 - Contact Levi & Korsinsky

August 21, 2025

September 15, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against CAPR

August 21, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

August 19, 2025

Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine

August 18, 2025

Securities Lawsuit Alert: Capricor Therapeutics, Inc. (CAPR) Investors - Contact Levi & Korsinsky Before September 15, 2025

August 18, 2025

Investors in Capricor Therapeutics, Inc. Should Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR

August 15, 2025

Capricor Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CAPR

August 15, 2025

Capricor Therapeutics, Inc. (CAPR) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 15, 2025

August 14, 2025

Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc.(CAPR)

August 12, 2025

Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 11, 2025

Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your Rights - CAPR

August 11, 2025

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

August 8, 2025

Capricor Therapeutics Sued for Securities Law Violations - Investors Should Contact Faruqi & Faruqi for More Information - CAPR

August 6, 2025

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

August 6, 2025

Contact Levi & Korsinsky by September 15, 2025 Deadline to Join Class Action Against Capricor Therapeutics, Inc. (CAPR)

July 31, 2025

Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy

July 28, 2025

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

July 11, 2025

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

June 20, 2025

Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

June 17, 2025

Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program

June 11, 2025

Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025

Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer

May 13, 2025

Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13

May 6, 2025

Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

May 5, 2025

Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day

April 1, 2025

Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 19, 2025

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

March 17, 2025

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

March 11, 2025

Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

March 7, 2025

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

March 4, 2025

Capricor Therapeutics to Participate in Upcoming Investor Conferences

February 9, 2025

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

January 1, 2025

Capricor Therapeutics to Present at Upcoming Investor Conferences

December 1, 2024

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

November 19, 2024

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 12, 2024

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

November 11, 2024

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

November 4, 2024

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

October 17, 2024

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

October 16, 2024

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

October 10, 2024

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

October 8, 2024

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

October 3, 2024

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

September 23, 2024

Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024

September 22, 2024

Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

September 16, 2024

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

September 5, 2024

Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 6, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 38 decks. Every deck is listed under its year.